Our results show that treatment with R848 (a TLR7/TLR8 ligand) or with Imiquimod (a TLR7 agonist) does not induce significant changes in cell differentiation in AML samples, although the observed effects varied among samples. This evidence concerns the gene TLR8 and acute myeloid leukemia.